` ABIO (ARCA Biopharma Inc) vs S&P 500 Comparison - Alpha Spread

ABIO
vs
S&P 500

Over the past 12 months, ABIO has underperformed S&P 500, delivering a return of -89% compared to the S&P 500's 9% growth.

Stocks Performance
ABIO vs S&P 500

Loading
ABIO
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ABIO vs S&P 500

Loading
ABIO
S&P 500
Difference
www.alphaspread.com

Performance By Year
ABIO vs S&P 500

Loading
ABIO
S&P 500
Add Stock

Competitors Performance
ARCA Biopharma Inc vs Peers

S&P 500
ABIO
ABBV
AMGN
GILD
VRTX
Add Stock

ARCA Biopharma Inc
Glance View

Economic Moat
None
Market Cap
10.9B USD
Industry
Biotechnology

ARCA Biopharma Inc. is a company rooted in the innovative confluence of biotechnology and personalized medicine, focused on pioneering solutions that aim to cater to individual genetic profiles. The company's journey is steered by a commitment to unraveling the complexities of cardiovascular diseases, where it applies its expertise in genetic targeting to develop tailored treatment options. By harnessing advanced genomic research, ARCA Biopharma seeks to understand the intricate relationship between genetic markers and heart-related health conditions, positioning itself uniquely within this specialized niche of the biotech sector. Its cornerstone project revolves around developing genetically-targeted therapies, which promise to enhance treatment efficacy and improve patient outcomes. Operating within the dynamic landscape of biotech, ARCA Biopharma monetizes its innovations through a multifaceted approach. Primarily, it invests in the rigorous development and clinical testing of its pipeline products, leading to regulatory approvals which open the doors to licensing agreements and commercialization opportunities. The company's strategic alliances, both with larger pharmaceutical firms and research institutions, enable it to leverage shared expertise and resources, thereby reducing development costs and expanding market reach. Through potential partnerships and collaborations, ARCA Biopharma capitalizes on its intellectual property, translating cutting-edge research into viable commercial products that address unmet medical needs in cardiovascular health.

ABIO Intrinsic Value
Not Available
Back to Top